The Multifaceted p21 (Cip1/Waf1/CDKN1A) in Cell Differentiation, Migration and Cancer Therapy
Open accessThe DOI matches its Crossref record; 213 of the 213 references it cites were found in a registry or an index.
Abstract
Loss of cell cycle control is characteristic of tumorigenesis. The protein p21 is the founding member of cyclin-dependent kinase inhibitors and an important versatile cell cycle protein. p21 is transcriptionally controlled by p53 and p53-independent pathways. Its expression is increased in response to various intra- and extracellular stimuli to arrest the cell cycle ensuring genomic stability. Apart from its roles in cell cycle regulation including mitosis, p21 is involved in differentiation, cell migration, cytoskeletal dynamics, apoptosis, transcription, DNA repair, reprogramming of induced pluripotent stem cells, autophagy and the onset of senescence. p21 acts either as a tumor suppressor or as an oncogene depending largely on the cellular context, its subcellular localization and posttranslational modifications. In the present review, we briefly mention the general functions of p21 and summarize its roles in differentiation, migration and invasion in detail. Finally, regarding its dual role as tumor suppressor and oncogene, we highlight the potential, difficulties and risks of using p21 as a biomarker as well as a therapeutic target.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
The limited in vitro lifetime of human diploid cell strains
Hayflick, L. (1965) · Experimental Cell Research · doi:10.1016/0014-4827(65)90211-9 · Cited by 5,876
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
Cell Migration: Integrating Signals from Front to Back
Ridley, A. J., Schwartz, M. A., Burridge, K., Firtel, R. A., Ginsberg, M. H., Borisy, G., Parsons, J. T., & Horwitz, A. R. (2003) · Science · doi:10.1126/science.1092053 · Cited by 4,978
A Perspective on Cancer Cell Metastasis
Chaffer, C. L., & Weinberg, R. A. (2011) · Science · doi:10.1126/science.1203543 · Cited by 4,807
p21 is a universal inhibitor of cyclin kinases
Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., & Beach, D. (1993) · Nature · doi:10.1038/366701a0 · Cited by 3,368
Requirement for p53 and p21 to Sustain G 2 Arrest After DNA Damage
Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J. P., Sedivy, J. M., Kinzler, K. W., & Vogelstein, B. (1998) · Science · doi:10.1126/science.282.5393.1497 · Cited by 2,803 · cited 1×
“In response to noxious environmental stimuli, p21 participates in the checkpoint control and initiates a temporary cell cycle arrest [34,35].”
Backgroundp21 in cancer: Intricate networks and multiple activities
Abbas, T., & Dutta, A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2657 · Cited by 2,712 · cited 10×
“Cytoplasmic p21 leads to an inhibition of multiple caspases and apoptotic effectors including pro-caspase-3, caspase-8, caspase-10, apoptosis signal-regulating kinase 1 and stress-activated protein kinase [2,3].”
BackgroundInfluentialMice Lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control
Deng, C., Zhang, P., Wade Harper, J., Elledge, S. J., & Leder, P. (1995) · Cell · doi:10.1016/0092-8674(95)90039-x · Cited by 2,113
Four faces of cellular senescence
Rodier, F., & Campisi, J. (2011) · Journal of Cell Biology · doi:10.1083/jcb.201009094 · Cited by 2,070
The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA
Waga, S., Hannon, G. J., Beach, D., & Stillman, B. (1994) · Nature · doi:10.1038/369574a0 · Cited by 1,655
New functional activities for the p21 family of CDK inhibitors.
LaBaer, J., Garrett, M. D., Stevenson, L. F., Slingerland, J. M., Sandhu, C., Chou, H. S., Fattaey, A., & Harlow, E. (1997) · Genes & Development · doi:10.1101/gad.11.7.847 · Cited by 1,402
Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen
Noda, A., Ning, Y., Venable, S. F., Pereira-Smith, O. M., & Smith, J. R. (1994) · Experimental Cell Research · doi:10.1006/excr.1994.1063 · Cited by 1,351
Hematopoietic Stem Cell Quiescence Maintained by p21 cip1/waf1
Cheng, T., Rodrigues, N., Shen, H., Yang, Y.-G., Dombkowski, D., Sykes, M., & Scadden, D. T. (2000) · Science · doi:10.1126/science.287.5459.1804 · Cited by 1,339
Suppression of induced pluripotent stem cell generation by the p53–p21 pathway
Hong, H., Takahashi, K., Ichisaka, T., Aoi, T., Kanagawa, O., Nakagawa, M., Okita, K., & Yamanaka, S. (2009) · Nature · doi:10.1038/nature08235 · Cited by 1,301 · cited 5×
“Cytoplasmic p21 elicits an inhibition of the Ras homolog gene family, member A (RhoA)/Rho-associated, coiled-coil containing protein kinase (ROCK)/LIM domain kinase (LIMK)-pathway by binding to ROCK, increases cofilin expression and cytoskeleton remodeling due to a loss of actin stress fibers favoring cell motility in…”
BackgroundInfluentialCDK inhibitors: Cell cycle regulators and beyond
Besson, A., Dowdy, S. F., & Roberts, J. M. (2008) · Developmental Cell · doi:10.1016/j.devcel.2008.01.013 · Cited by 1,152
Cheng, M., Olivier, P., Diehl, J. A., Fero, M., Roussel, M. F., Roberts, J. M., & Sherr, C. J. (1999) · The EMBO Journal · doi:10.1093/emboj/18.6.1571 · Cited by 1,142 · cited 1×
“This is supported by another study showing that primary mouse embryonic fibroblasts (MEFs) lacking p21 and its family member p27 failed to assemble detectable amounts of cyclin D/Cdk4 complexes [38].”
BackgroundZhou, B. P., Liao, Y., Xia, W., Spohn, B., Lee, M.-H., & Hung, M.-C. (2001) · Nature Cell Biology · doi:10.1038/35060032 · Cited by 1,135
Senescence-associated reprogramming promotes cancer stemness
Milanovic, M., Fan, D. N. Y., Belenki, D., Däbritz, J. H. M., Zhao, Z., Yu, Y., Dörr, J. R., Dimitrova, L., Lenze, D., Monteiro Barbosa, I. A., et al. (2018) · Nature · doi:10.1038/nature25167 · Cited by 1,131
Linking the p53 tumour suppressor pathway to somatic cell reprogramming
Kawamura, T., Suzuki, J., Wang, Y. V., Menendez, S., Morera, L. B., Raya, A., Wahl, G. M., & Belmonte, J. C. I. (2009) · Nature · doi:10.1038/nature08311 · Cited by 1,115 · cited 5×
“Cytoplasmic p21 elicits an inhibition of the Ras homolog gene family, member A (RhoA)/Rho-associated, coiled-coil containing protein kinase (ROCK)/LIM domain kinase (LIMK)-pathway by binding to ROCK, increases cofilin expression and cytoskeleton remodeling due to a loss of actin stress fibers favoring cell motility in…”
BackgroundInfluentialThe role of the cyclin-dependent kinase inhibitor p21 in apoptosis.
Gartel, A. L., & Tyner, A. L. (2002) · PubMed · Cited by 1,075
p53-Independent Expression of p21 Cip1 in Muscle and Other Terminally Differentiating Cells
Parker, S. B., Eichele, G., Zhang, P., Rawls, A., Sands, A. T., Bradley, A., Olson, E. N., Harper, J. W., & Elledge, S. J. (1995) · Science · doi:10.1126/science.7863329 · Cited by 1,032
Liu, M., Lee, M. H., Cohen, M., Bommakanti, M., & Freedman, L. P. (1996) · Genes & Development · doi:10.1101/gad.10.2.142 · Cited by 890
Targeting polo-like kinase 1 for cancer therapy
Strebhardt, K., & Ullrich, A. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1841 · Cited by 841
Lost in Transcription: p21 Repression, Mechanisms, and Consequences
Gartel, A. L., & Radhakrishnan, S. K. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3995 · Cited by 818
Targeting oncogenic Myc as a strategy for cancer treatment
Chen, H., Liu, H., & Qing, G. (2018) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-018-0008-7 · Cited by 806
Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit
Gu, Y., Turck, C. W., & Morgan, D. O. (1993) · Nature · doi:10.1038/366707a0 · Cited by 764
New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment?
Coqueret, O. (2003) · Trends in Cell Biology · doi:10.1016/s0962-8924(02)00043-0 · Cited by 751
Cancer stem cells: The challenges ahead
Medema, J. P. (2013) · Nature Cell Biology · doi:10.1038/ncb2717 · Cited by 741
Transcriptional Regulation of the p21(WAF1/CIP1)Gene
Gartel, A. L., & Tyner, A. L. (1999) · Experimental Cell Research · doi:10.1006/excr.1998.4319 · Cited by 664
Cell cycle arrest through indirect transcriptional repression by p53: I have a DREAM
Engeland, K. (2018) · Cell Death & Differentiation · doi:10.1038/cdd.2017.172 · Cited by 656
Apoptosis inhibitory activity of cytoplasmic p21Cip1/WAF1 in monocytic differentiation
Asada, M. (1999) · The EMBO Journal · doi:10.1093/emboj/18.5.1223 · Cited by 586
MicroRNAs in the miR-106b family regulate p21/CDKN1A and promote cell cycle progression
Ivanovska, I., Ball, A. S., Diaz, R. L., Magnus, J. F., Kibukawa, M., Schelter, J. M., Kobayashi, S. V., Lim, L., Burchard, J., Jackson, A. L., et al. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01977-07 · Cited by 561
Ruijtenberg, S., & van den Heuvel, S. (2016) · Cell Cycle · doi:10.1080/15384101.2015.1120925 · Cited by 553
Jiang, H., Lin, J., Su, Z., Collart, F., Huberman, E., & Fisher, P. B. (1994) · PubMed · Cited by 495
p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug
Wang, S.-P., Wang, W.-L., Chang, Y.-L., Wu, C.-T., Chao, Y.-C., Kao, S.-H., Yuan, A., Lin, C.-W., Yang, S.-C., Chan, W.-K., et al. (2009) · Nature Cell Biology · doi:10.1038/ncb1875 · Cited by 493
Resistance to Apoptosis Conferred by Cdk Inhibitors During Myocyte Differentiation
Wang, J., & Walsh, K. (1996) · Science · doi:10.1126/science.273.5273.359 · Cited by 489
p21: a two-faced genome guardian.
Georgakilas, A. G., Martin, O. A., & Bonner, W. M. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.02.001 · Cited by 489
p21 and p27: roles in carcinogenesis and drug resistance
Abukhdeir, A. M., & Park, B. H. (2008) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399408000744 · Cited by 463
Current progress of siRNA/shRNA therapeutics in clinical trials
Burnett, J. C., Rossi, J. J., & Tiemann, K. (2011) · Biotechnology Journal · doi:10.1002/biot.201100054 · Cited by 444
Roninson, I. B. (2002) · Cancer Letters · doi:10.1016/s0304-3835(01)00847-3 · Cited by 443 · cited 3×
“Cytoplasmic expression of p21, which is common in human tumors, is linked to aggressiveness and poor prognosis [2,4].”
BackgroundLi, Y., Dowbenko, D., & Lasky, L. A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109062200 · Cited by 442
Kippin, T. E., Martens, D. J., & van der Kooy, D. (2005) · Genes & Development · doi:10.1101/gad.1272305 · Cited by 442
Multiple roles of the cell cycle inhibitor p21CDKN1A in the DNA damage response
Cazzalini, O., Scovassi, A. I., Savio, M., Stivala, L. A., & Prosperi, E. (2010) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2010.01.009 · Cited by 433
Chang, B.-D., Watanabe, K., Broude, E. V., Fang, J., Poole, J. C., Kalinichenko, T. V., & Roninson, I. B. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.8.4291 · Cited by 432
Tumor susceptibility of p21(Waf1/Cip1)-deficient mice.
Martín‐Caballero, J., Flores, J. M., García, P., & Serrano, M. (2001) · PubMed · Cited by 429
Guo, K., Wang, J., Andrés, V., Smith, R. C., & Walsh, K. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.7.3823 · Cited by 423
Examination of the expanding pathways for the regulation of p21 expression and activity
Jung, Y.-S., Qian, Y., & Chen, X. (2010) · Cellular Signalling · doi:10.1016/j.cellsig.2010.01.013 · Cited by 423
Barr, A. R., Cooper, S., Heldt, F. S., Butera, F., Stoy, H., Mansfeld, J., Novák, B., & Bakal, C. (2017) · Nature Communications · doi:10.1038/ncomms14728 · Cited by 403 · cited 1×
“Using live single-cell measurements it has recently been shown that the amount of p21 and the time period of its increased expression contribute to the decision between cell cycle arrest and the repair of incomplete replicated DNA maintaining genomic stability [36].”
BackgroundMissero, C., Calautti, E., Eckner, R., Chin, J., Tsai, L. H., Livingston, D. M., & Dotto, G. P. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.12.5451 · Cited by 328
McConnell, B. B., Starborg, M., Brookes, S., & Peters, G. (1998) · Current Biology · doi:10.1016/s0960-9822(98)70137-x · Cited by 314 · cited 1×
“Apoptosis inhibition/activation Both Oncogene/Tumor suppressor [51,52] Autophagy induction/inhibition Cytoplasm ? [54,56] Cell cycle arrest Nucleus Tumor suppressor [1,18] Cell cycle progression Cytoplasm Oncogene [37,39] Chromosomal stability Nucleus Tumor suppressor [23–25] Differentiation Both Both [63,64] DNA synt…”
BackgroundGalanos, P., Vougas, K., Walter, D., Polyzos, A., Maya-Mendoza, A., Haagensen, E. J., Kokkalis, A., Roumelioti, F.-M., Gagos, S., Tzetis, M., et al. (2016) · Nature Cell Biology · doi:10.1038/ncb3378 · Cited by 308 · cited 5×
“In support of this observation, sustained expression of p21 exhibits oncogenic functions in a p53-null background leading to escaping senescence and chemoresistance [62].”
BackgroundMethodInfluentialCell-cycle restriction limits DNA damage and maintains self-renewal of leukaemia stem cells
Viale, A., De Franco, F., Orleth, A., Cambiaghi, V., Giuliani, V., Bossi, D., Ronchini, C., Ronzoni, S., Muradore, I., Monestiroli, S., et al. (2009) · Nature · doi:10.1038/nature07618 · Cited by 305
Lacy, E. R., Filippov, I., Lewis, W. S., Otieno, S., Xiao, L., Weiss, S., Hengst, L., & Kriwacki, R. W. (2004) · Nature Structural & Molecular Biology · doi:10.1038/nsmb746 · Cited by 305
Franklin, D. S., Godfrey, V. L., O'Brien, D. A., Deng, C., & Xiong, Y. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.16.6147-6158.2000 · Cited by 297
Valente, L. J., Gray, D. H. D., Michalak, E. M., Pinon-Hofbauer, J., Egle, A., Scott, C. L., Janic, A., & Strasser, A. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.04.012 · Cited by 291
p21WAF1 and tumourigenesis: 20 years after
Warfel, N. A., & El-Deiry, W. S. (2013) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32835b639e · Cited by 286
Di Cunto, F., Topley, G., Calautti, E., Hsiao, J., Ong, L., Seth, P. K., & Dotto, G. P. (1998) · Science · doi:10.1126/science.280.5366.1069 · Cited by 275
Role of p21 in Apoptosis and Senescence of Human Colon Cancer Cells Treated with Camptothecin
Han, Z., Wei, W., Dunaway, S., Darnowski, J. W., Calabresi, P., Sedivy, J., Hendrickson, E. A., Balan, K. V., Pantazis, P., & Wyche, J. H. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m112401200 · Cited by 262
p21(WAF1) Mediates Cell-Cycle Inhibition, Relevant to Cancer Suppression and Therapy
El-Deiry, W. S. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-2055 · Cited by 256
Histone deacetylase inhibitors: Signalling towards p21cip1/waf1
Ocker, M., & Schneider-Stock, R. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.03.001 · Cited by 250
Liao, T., & Yang, M. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12096 · Cited by 239
Zhang, Y., Fujita, N., & Tsuruo, T. (1999) · Oncogene · doi:10.1038/sj.onc.1202426 · Cited by 237
p21Waf1/Cip1 as a therapeutic target in breast and other cancers
Weiss, R. H. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00308-8 · Cited by 237
Dutto, I., Tillhon, M., Cazzalini, O., Stivala, L. A., & Prosperi, E. (2015) · Archives of Toxicology · doi:10.1007/s00204-014-1430-4 · Cited by 236
Selective Autophagy Regulates Cell Cycle in Cancer Therapy
Zheng, K., He, Z., Kitazato, K., & Wang, Y. (2019) · Theranostics · doi:10.7150/thno.30308 · Cited by 227
Cytoplasmic p21 expression levels determine cisplatin resistance in human testicular cancer
Koster, R., di Pietro, A., Timmer-Bosscha, H., Gibcus, J. H., van den Berg, A., Suurmeijer, A. J., Bischoff, R., Gietema, J. A., & de Jong, S. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41939 · Cited by 226
Poluha, W., Poluha, D. K., Chang, B., Crosbie, N. E., Schonhoff, C. M., Kilpatrick, D. L., & Ross, A. H. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.4.1335 · Cited by 223
Capparelli, C., Chiavarina, B., Whitaker-Menezes, D., Pestell, T. G., Pestell, R. G., Hulit, J., Andò, S., Howell, A., Martinez-Outschoorn, U. E., Sotgia, F., et al. (2012) · Cell Cycle · doi:10.4161/cc.21884 · Cited by 221
Cell cycle regulation by the intrinsically disordered proteins p21 and p27
Yoon, M.-K., Mitrea, D. M., Ou, L., & Kriwacki, R. W. (2012) · Biochemical Society Transactions · doi:10.1042/bst20120092 · Cited by 220
The p53/p21 Complex Regulates Cancer Cell Invasion and Apoptosis by Targeting Bcl-2 Family Proteins
Kim, E. M., Jung, C.-H., Kim, J., Hwang, S.-G., Park, J. K., & Um, H.-D. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2098 · Cited by 211
Biggs, J. R., Kudlow, J. E., & Kraft, A. S. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.2.901 · Cited by 210
Fang, L., Igarashi, M., Leung, J., Sugrue, M. M., Lee, S. W., & Aaronson, S. A. (1999) · Oncogene · doi:10.1038/sj.onc.1202615 · Cited by 207
Cip/Kip proteins: more than just CDKs inhibitors: Figure 1.
Denicourt, C., & Dowdy, S. F. (2004) · Genes & Development · doi:10.1101/gad.1205304 · Cited by 203
Topley, G. I., Okuyama, R., Gonzales, J. G., Conti, C., & Dotto, G. P. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.16.9089 · Cited by 197
Roman-Gomez, J., Castillejo, J. A., Jimenez, A., Gonzalez, M. G., Moreno, F., Rodriguez, M. D. C., Barrios, M., Maldonado, J., & Torres, A. (2002) · Blood · doi:10.1182/blood.v99.7.2291 · Cited by 193
Matsumura, I., Ishikawa, J., Nakajima, K., Oritani, K., Tomiyama, Y., Miyagawa, J.-I., Kato, T., Miyazaki, H., Matsuzawa, Y., & Kanakura, Y. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.5.2933 · Cited by 190
Alteration of Epigenetic Regulation by Long Noncoding RNAs in Cancer
Morlando, M., & Fatica, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020570 · Cited by 189
Child, E. S., & Mann, D. J. (2006) · Cell Cycle · doi:10.4161/cc.5.12.2863 · Cited by 184
Liu, M., Casimiro, M. C., Wang, C., Shirley, L. A., Jiao, X., Katiyar, S., Ju, X., Li, Z., Yu, Z., Zhou, J., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910009106 · Cited by 171
Wang, Y. A., Elson, A., & Leder, P. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.26.14590 · Cited by 170
Xia, W., Chen, J.-S., Zhou, X., Sun, P.-R., Lee, D.-F., Liao, Y., Zhou, B. P., & Hung, M.-C. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0527 · Cited by 166
Cytoplasmic p21Cip1 Is Involved in Ras-induced Inhibition of the ROCK/LIMK/Cofilin Pathway
Lee, S., & Helfman, D. M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m306968200 · Cited by 164
Yang, W., Mathew, J., Velcich, A., Edelmann, W., Kucherlapati, R., Lipkin, M., Yang, K., & Augenlicht, L. H. (2001) · PubMed · Cited by 164
Senescence and senotherapeutics: a new field in cancer therapy
Myrianthopoulos, V., Evangelou, K., Vasileiou, P. V. S., Cooks, T., Vassilakopoulos, T. P., Pangalis, G. A., Kouloukoussa, M., Kittas, C., Georgakilas, A. G., & Gorgoulis, V. G. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.08.006 · Cited by 160 · cited 1×
“Alternatively, a possible interfering strategy would be to reduce its nuclear oncogenic properties by blocking its PCNA binding with small molecules like T2AA [218], by blocking error-prone DNA repair [219] or by the targeted elimination of therapy-resistant senescent cells with senotherapeutics including senolytics a…”
BackgroundZezula, J., Casaccia‐Bonnefil, P., Ezhevsky, S. A., Osterhout, D. J., Levine, J. M., Dowdy, S. F., Chao, M. V., & Koff, A. (2001) · EMBO Reports · doi:10.1093/embo-reports/kve008 · Cited by 160
Phosphorylation of p21 in G2/M Promotes Cyclin B-Cdc2 Kinase Activity
Dash, B. C., & El‐Deiry, W. S. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.8.3364-3387.2005 · Cited by 160
Cytoplasmic p21Cip1/WAF1 regulates neurite remodeling by inhibiting Rho-kinase activity
Tanaka, H., Yamashita, T., Asada, M., Mizutani, S., Yoshikawa, H., & Tohyama, M. (2002) · The Journal of Cell Biology · doi:10.1083/jcb.200202071 · Cited by 157
Repair Defect in p21 WAF1/CIP1 -/- human cancer cells.
McDonald, E. R., Wu, G. S., Waldman, T. A., & El‐Deiry, W. S. (1996) · PubMed · Cited by 155
p21 Is a Critical CDK2 Regulator Essential for Proliferation Control in Rb-deficient Cells
Brugarolas, J., Bronson, R. T., & Jacks, T. (1998) · The Journal of Cell Biology · doi:10.1083/jcb.141.2.503 · Cited by 153
Hengel, S. R., Spies, M., & Spies, M. (2017) · Cell chemical biology · doi:10.1016/j.chembiol.2017.08.027 · Cited by 152
Inhibition of nucleotide excision repair by the cyclin-dependent kinase inhibitor p21
Pan, Z.-Q., Reardon, J. T., Li, L., Flores-Rozas, H., Legerski, R., Sancar, A., & Hurwitz, J. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.37.22008 · Cited by 151 · cited 1×
“Apoptosis inhibition/activation Both Oncogene/Tumor suppressor [51,52] Autophagy induction/inhibition Cytoplasm ? [54,56] Cell cycle arrest Nucleus Tumor suppressor [1,18] Cell cycle progression Cytoplasm Oncogene [37,39] Chromosomal stability Nucleus Tumor suppressor [23–25] Differentiation Both Both [63,64] DNA synt…”
BackgroundCheng, H.-C., Qiu, L., Ma, J., Zhang, H., Cheng, M., Li, W., Zhao, X., & Liu, K. (2010) · Molecular Biology Reports · doi:10.1007/s11033-010-0665-2 · Cited by 150
P53 mutations and cancer: a tight linkage
Perri, F., Pisconti, S., & Scarpati, G. D. V. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.12.40 · Cited by 148
Multiple degradation pathways regulate versatile CIP/KIP CDK inhibitors
Starostina, N. G., & Kipreos, E. T. (2012) · Trends in Cell Biology · doi:10.1016/j.tcb.2011.10.004 · Cited by 147 · cited 1×
“The short-lived p21 protein is degraded via different ubiquitin-dependent and -independent pathways [3,12].”
BackgroundPharmacologic Activation of p53 by Small-Molecule MDM2 Antagonists
Shen, H., & G. Maki, C. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211795222603 · Cited by 147
Jin, Y. H., Yoo, K. J., Lee, Y. H., & Lee, S. K. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m001902200 · Cited by 147
Loss of cyclin‐dependent kinase inhibitors produces adipocyte hyperplasia and obesity
Naaz, A., Holsberger, D. R., Iwamoto, G. A., Nelson, A., Kiyokawa, H., & Cooke, P. S. (2004) · The FASEB Journal · doi:10.1096/fj.04-2631fje · Cited by 144
Wang, Y., Blandino, G., & Givol, D. (1999) · Oncogene · doi:10.1038/sj.onc.1202632 · Cited by 144
Are p27 and p21 Cytoplasmic Oncoproteins?
Blagosklonny, M. V. (2002) · Cell Cycle · doi:10.4161/cc.1.6.262 · Cited by 140
Punchihewa, C., Inoue, A., Hishiki, A., Fujikawa, Y., Connelly, M., Evison, B., Shao, Y., Heath, R., Kuraoka, I., Rodrigues, P., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.353201 · Cited by 135
Cellular senescence and cancer chemotherapy resistance
Gordon, R. R., & Nelson, P. S. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.01.002 · Cited by 134
Kitaura, H., Shinshi, M., Uchikoshi, Y., Ono, T., Tsurimoto, T., Yoshikawa, H., Iguchi-Ariga, S. M. M., & Ariga, H. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.14.10477 · Cited by 129
Less understood issues: p21Cip1 in mitosis and its therapeutic potential
Kreis, N., Louwen, F., & Yuan, J. (2014) · Oncogene · doi:10.1038/onc.2014.133 · Cited by 129
Self-citationTian, H., Wittmack, E. K., & Jorgensen, T. J. (2000) · PubMed · Cited by 125
Zhang, Y., Wang, Z., & Magnuson, N. S. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0388 · Cited by 125
Podust, V. N., Podust, L. M., Goubin, F., Ducommun, B., & Huebscher, U. (1995) · Biochemistry · doi:10.1021/bi00027a039 · Cited by 124
Lincet, H., Poulain, L., Rémy, J.-S., Deslandes, E., Duigou, F., Gauduchon, P., & Staedel, C. (2000) · Cancer Letters · doi:10.1016/s0304-3835(00)00586-3 · Cited by 124
Schwaller, J., Koeffler, H. P., Niklaus, G., Loetscher, P., Nagel, S., Fey, M., & Tobler, A. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117806 · Cited by 122
Therapeutic targeting of cancer cell cycle using proteasome inhibitors
Rastogi, N., & Mishra, D. P. (2012) · Cell Division · doi:10.1186/1747-1028-7-26 · Cited by 121
Gartel, A. L., Serfas, M. S., Gartel, M., Goufman, E., Wu, G. S., El-Deiry, W. S., & Tyner, A. L. (1996) · Experimental Cell Research · doi:10.1006/excr.1996.0264 · Cited by 120
The conflicting roles of the cdk inhibitor p21(CIP1/WAF1) in apoptosis
Gartel, A. L. (2005) · Leukemia Research · doi:10.1016/j.leukres.2005.04.023 · Cited by 120
Chen, Z., Chen, X., Chen, P., Yu, S., Nie, F., Lu, B., Zhang, T., Zhou, Y., Chen, Q., Wei, C., et al. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.484 · Cited by 120
Mohapatra, P., Preet, R., Das, D., Satapathy, S. R., Choudhuri, T., Wyatt, M. D., & Kundu, C. N. (2012) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504012x13473664562628 · Cited by 116
Mitchell, K. O., & El‐Deiry, W. S. (1999) · PubMed · Cited by 114
Mirk/Dyrk1B Mediates Survival during the Differentiation of C2C12Myoblasts
Mercer, S. E., Ewton, D. Z., Deng, X., Lim, S., Mazur, T. R., & Friedman, E. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413594200 · Cited by 113
Pivotal Role of the Cyclin-dependent Kinase Inhibitor p21WAF1/CIP1 in Apoptosis and Autophagy
Fujiwara, K., Daido, S., Yamamoto, A., Kobayashi, R., Yokoyama, T., Aoki, H., Iwado, E., Shinojima, N., Kondo, Y., & Kondo, S. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m611043200 · Cited by 112
p21 delays tumor onset by preservation of chromosomal stability
Barboza, J. A., Liu, G., Ju, Z., El-Naggar, A. K., & Lozano, G. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606343104 · Cited by 110
Subcellular localisation of cyclin B, Cdc2 and p21WAF1/CIP1 in breast cancer
Winters, Z., Hunt, N., Bradburn, M. J., Royds, J. A., Turley, H., Harris, A. L., & Norbury, C. J. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00327-6 · Cited by 110
Winters, Z. E., Leek, R. D., Bradburn, M. J., Norbury, C. J., & Harris, A. L. (2003) · Breast Cancer Research · doi:10.1186/bcr654 · Cited by 106
Patterns of chromosomal imbalances in invasive breast cancer
Richard, F., Pacyna-Gengelbach, M., Schlüns, K., Fleige, B., Winzer, K. J., Szymaś, J., Dietel, M., Petersen, I., & Schwendel, A. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20000520)89:3<305::aid-ijc15>3.0.co;2-8 · Cited by 103
Involvement of p21(WAF1/Cip1) and p27(Kip1) in intestinal epithelial cell differentiation
Tian, J. Q., & Quaroni, A. (1999) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.1999.276.6.c1245 · Cited by 102
Li, X. L., Hara, T., Choi, Y., Subramanian, M., Francis, P., Bilke, S., Walker, R. L., Pineda, M., Zhu, Y., Yang, Y., et al. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.01043-13 · Cited by 101
Dai, M., Al-Odaini, A. A., Fils-Aimé, N., Villatoro, M. A., Guo, J., Arakelian, A., Rabbani, S. A., Ali, S., & Lebrun, J. J. (2013) · Breast Cancer Research · doi:10.1186/bcr3441 · Cited by 100
Yuan, J., Sanhaji, M., Krämer, A., Reindl, W., Hofmann, M., Kreis, N., Zimmer, B., Berg, T., & Strebhardt, K. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.06.031 · Cited by 98
Self-citationYew, T., Chiu, F., Tsai, C., Chen, H., Lee, W., Chen, Y., Chang, M.-C., & Hung, S. (2011) · Aging Cell · doi:10.1111/j.1474-9726.2011.00676.x · Cited by 95
Soria, G., Speroni, J., Podhajcer, O. L., Prives, C., & Gottifredi, V. (2008) · Journal of Cell Science · doi:10.1242/jcs.027730 · Cited by 94
Casini, T., & Pelicci, P. G. (1999) · Oncogene · doi:10.1038/sj.onc.1202630 · Cited by 93
The Senescence–Stemness Alliance – A Cancer-Hijacked Regeneration Principle
Milanovic, M., Yu, Y., & Schmitt, C. A. (2018) · Trends in Cell Biology · doi:10.1016/j.tcb.2018.09.001 · Cited by 92
A Dual Role of p21 in Stem Cell Aging
Ju, Z., Choudhury, A. R., & Rudolph, K. L. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1395.036 · Cited by 91
Hwang, C. Y., Lee, C., & Kwon, K. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.01758-08 · Cited by 90
Kondo, S., Barna, B. P., Kondo, Y., Tanaka, Y., Casey, G., Liu, J., Morimura, T., Kaakaji, R., Peterson, J. W., Werbel, B., et al. (1996) · PubMed · Cited by 88
Inoue, N., Yahagi, N., Yamamoto, T., Ishikawa, M., Watanabe, K., Matsuzaka, T., Nakagawa, Y., Takeuchi, Y., Kobayashi, K., Takahashi, A., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m801824200 · Cited by 87
Liu, Y., Encinas, M., Comella, J. X., Aldea, M., & Gallego, C. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.7.2662-2672.2004 · Cited by 83
Role of p21Cip1/Waf1 in cell-cycle exit of endomitotic megakaryocytes
Baccini, V., Roy, L., Vitrat, N., Chagraoui, H., Sabri, S., Couedic, J. P. L., Debili, N., Wendling, F., & Vainchenker, W. (2001) · Blood · doi:10.1182/blood.v98.12.3274 · Cited by 82
Cytoplasmic p21 is a potential predictor for cisplatin sensitivity in ovarian cancer
Xia, X., Ma, Q., Xiao, L., Ji, T., Chen, P., Xu, H., Li, K., Fang, Y., Weng, D., Weng, Y., et al. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-399 · Cited by 82
Cytoplasmic translocation of p21 mediates NUPR1‐induced chemoresistance
Vincent, A. J., Ren, S., Harris, L. G., Devine, D. J., Samant, R. S., Fodstad, Ø., & Shevde, L. A. (2012) · FEBS Letters · doi:10.1016/j.febslet.2012.07.063 · Cited by 80
miRNAs: micro-managers of anticancer combination therapies
van Beijnum, J. R., Giovannetti, E., Poel, D., Nowak-Sliwinska, P. M., & Griffioen, A. W. (2017) · Angiogenesis · doi:10.1007/s10456-017-9545-x · Cited by 80
Tumorigenic activity of p21Waf1/Cip1 in thymic lymphoma
de la Cueva, E., Garcı́a-Cao, I., Herranz, M., López, P., Garcı́a, P., Flores, J. M., Serrano, M., Fernández‐Piqueras, J., & Martín‐Caballero, J. (2006) · Oncogene · doi:10.1038/sj.onc.1209432 · Cited by 77
Differential effects of p21(WAF1/CIP1) deficiency on MMTV-ras and MMTV-myc mammary tumor properties.
Bearss, D. J., Lee, R. J., Troyer, D. A., Pestell, R. G., & Windle, J. J. (2002) · PubMed · Cited by 77
CRISPR–Cas9 a boon or bane: the bumpy road ahead to cancer therapeutics
Ghosh, D., Venkataramani, P., Nandi, S., & Bhattacharjee, S. (2019) · Cancer Cell International · doi:10.1186/s12935-019-0726-0 · Cited by 76
An antisense oligodeoxynucleotide to p21(Waf1/Cip1) causes apoptosis in human breast cancer cells.
Fan, Y., Borowsky, A. D., & Weiss, R. H. (2003) · PubMed · Cited by 74
Yamamoto, H., Soh, J., Shirin, H., Xing, W.-Q., Lim, J. T., Yao, Y., Slosberg, E. D., Tomita, N., Schieren, I., & Weinstein, I. B. (1999) · Oncogene · doi:10.1038/sj.onc.1202269 · Cited by 73
Adimoolam, S., Lin, C. X., & Ford, J. M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m102240200 · Cited by 71
p21WAF1/CIP1 and cancer: A shifting paradigm?
Gartel, A. L. (2009) · BioFactors · doi:10.1002/biof.26 · Cited by 71
Cooperative actions of p21WAF1 and p53 induce Slug protein degradation and suppress cell invasion
Kim, J., Bae, S., An, S., Park, J. K., Kim, E. M., Hwang, S., Kim, W., & Um, H. (2014) · EMBO Reports · doi:10.15252/embr.201438587 · Cited by 69
Okuma, A., Hanyu, A., Watanabe, S., & Hara, E. (2017) · Nature Communications · doi:10.1038/s41467-017-02281-x · Cited by 69
Lats2 phosphorylates p21/CDKN1A after UV irradiation and regulates apoptosis
Suzuki, H., Yabuta, N., Okada, N., Torigata, K., Aylon, Y., Oren, M., & Nojima, H. (2013) · Journal of Cell Science · doi:10.1242/jcs.125815 · Cited by 68
Mutational signatures reveal the role of RAD52 in p53-independent p21-driven genomic instability
Galanos, P., Pappas, G., Polyzos, A., Kotsinas, A., Svolaki, I., Giakoumakis, N. N., Glytsou, C., Pateras, I. S., Swain, U., Souliotis, V. L., et al. (2018) · Genome Biology · doi:10.1186/s13059-018-1401-9 · Cited by 67
The Cyclin-Dependent Kinase Inhibitor p21CDKN1A as a Target of Anti-Cancer Drugs
Stivala, L. A., Cazzalini, O., & Prosperi, E. (2012) · Current Cancer Drug Targets · doi:10.2174/156800912799095126 · Cited by 66
Freemerman, A. J., Vrana, J. A., Tombes, R. M., Jiang, H., Chellappan, S., Pb, F., & Grant, S. (1997) · Leukemia · doi:10.1038/sj.leu.2400625 · Cited by 65
Pérez‐Tenorio, G., Berglund, F., Merca, A. E., Nordenskjöld, B. A., Rutqvist, L. E., Skoog, L. K., & Stål, O. (2006) · International Journal of Oncology · doi:10.3892/ijo.28.5.1031 · Cited by 65
Héliez, C., Baricault, L., Barboule, N., & Valette, A. (2003) · Oncogene · doi:10.1038/sj.onc.1206409 · Cited by 64
Dai, M., Al-Odaini, A. A., Arakelian, A., Rabbani, S. A., Ali, S., & Lebrun, J. J. (2012) · Breast Cancer Research · doi:10.1186/bcr3322 · Cited by 62
A novel p21 attenuator which is structurally related to sorafenib
Wettersten, H. I., Hwang, S. H., Li, C., Shiu, E. Y. C., Wecksler, A. T., Hammock, B. D., & Weiss, R. H. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.23374 · Cited by 61
Starostina, N. G., Simpliciano, J. M., McGuirk, M. A., & Kipreos, E. T. (2010) · Developmental Cell · doi:10.1016/j.devcel.2010.10.013 · Cited by 59
Inoue, H., Hwang, S. H., Wecksler, A. T., Hammock, B. D., & Weiss, R. H. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.12.9.17680 · Cited by 59
Sun, Y., Yang, S., Sun, N., & Chen, J. (2014) · Pancreas · doi:10.1097/mpa.0000000000000074 · Cited by 58
A role for E2F1 in Ras activation of p21(WAF1/CIP1) transcription
Gartel, A. L., Najmabadi, F., Goufman, E., & Tyner, A. L. (2000) · Oncogene · doi:10.1038/sj.onc.1203411 · Cited by 57
Disruption of TGF-β growth inhibition by oncogenic ras is linked to p27Kip1 mislocalization
Liu, X., Sun, Y., Ehrlich, M., Lu, T., Kloog, Y., Weinberg, R. A., Lodish, H. F., & Henis, Y. I. (2000) · Oncogene · doi:10.1038/sj.onc.1203991 · Cited by 57
Stivala, L. A., Riva, F., Cazzalini, O., Savio, M., & Prosperi, E. (2001) · Oncogene · doi:10.1038/sj.onc.1204132 · Cited by 57
p21 promotes error-free replication-coupled DNA double-strand break repair
Mauro, M., Rego, M. A., Boisvert, R. A., Esashi, F., Cavallo, F., Jasin, M., & Howlett, N. G. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks612 · Cited by 56 · cited 1×
“Apoptosis inhibition/activation Both Oncogene/Tumor suppressor [51,52] Autophagy induction/inhibition Cytoplasm ? [54,56] Cell cycle arrest Nucleus Tumor suppressor [1,18] Cell cycle progression Cytoplasm Oncogene [37,39] Chromosomal stability Nucleus Tumor suppressor [23–25] Differentiation Both Both [63,64] DNA synt…”
Backgroundp21Cip-1/SDI-1/WAF-1 Gene Is Involved in Chondrogenic Differentiation of ATDC5 Cells in Vitro
Negishi, Y., Ui, N., Nakajima, M., Kawashima, K., Maruyama, K., 知子, 滝., & Endo, H. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010127200 · Cited by 56
p21WAF1/CIP1 Acts as a Brake in Osteoblast Differentiation
Bellosta, P., Masramon, L., Mansukhani, A., & Basilico, C. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.5.818 · Cited by 56
Brap2 Functions as a Cytoplasmic Retention Protein for p21 during Monocyte Differentiation
Asada, M., Ohmi, K., Delia, D., Enosawa, S., Suzuki, S., Yuo, A., Suzuki, H., & Mizutani, S. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.18.8236-8243.2004 · Cited by 55
GATA-1 directly regulates p21 gene expression during erythroid differentiation
Papetti, M., Wontakal, S. N., Stopka, T., & Skoultchi, A. I. (2010) · Cell Cycle · doi:10.4161/cc.9.10.11602 · Cited by 54
Yu, Y., Zhang, M., Wang, N., Li, Q., Yang, J., Yan, S., He, X., Ji, G., & Miao, L. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0768-6 · Cited by 54
Weiss, R. H., Marshall, D., Howard, L. L., Corbacho, A. M., Cheung, A., & Sawai, E. T. (2002) · Cancer Letters · doi:10.1016/s0304-3835(02)00495-0 · Cited by 52
p21 as a Transcriptional Co-Repressor of S-Phase and Mitotic Control Genes
Ferrándiz, N., Caraballo, J. M., García-Gutiérrez, L., Devgan, V., Rodríguez‐Paredes, M., Lafita‐Navarro, M. C., Bretones, G., Quintanilla, A., Muñoz-Alonso, M. J., Blanco, R. E., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037759 · Cited by 52
P21 Deficiency Delays Regeneration of Skeletal Muscular Tissue
Chinzei, N., Hayashi, S., Ueha, T., Fujishiro, T., Kanzaki, N., Hashimoto, S., Sakata, S., Kihara, S., Haneda, M., Sakai, Y., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125765 · Cited by 51
p21CIP1 mediates reciprocal switching between proliferation and invasion during metastasis
Qian, X., Hulit, J., Suyama, K., Eugenín, E. A., Belbin, T. J., Loudig, O. D., Смирнова, Т. А., Zhou, Z. N., Segall, J. E., Locker, J. D., et al. (2012) · Oncogene · doi:10.1038/onc.2012.249 · Cited by 49
p21 (WAF1/CIP1) Mediates the Growth Response to TGF-b in Human Epithelial Cells
Bachman, K. E., Blair, B. G., BRENNER, K. R., Bardelli, A., Arena, S., Zhou, S., Hicks, J. L., Marzo, A. M. D., Argani, P., & Park, B. H. (2004) · Cancer Biology & Therapy · doi:10.4161/cbt.3.2.666 · Cited by 49
p21WAF1/CIP1 gene is inactivated in metastatic prostatic cancer cell lines by promoter methylation
Bott, S., Arya, M., Kirby, R. S., & Williamson, M. P. (2005) · Prostate Cancer and Prostatic Diseases · doi:10.1038/sj.pcan.4500822 · Cited by 48
p21Waf1/Cip1 deficiency causes multiple mitotic defects in tumor cells
Kreis, N., Sanhaji, M., Rieger, M. A., Louwen, F., & Yuan, J. (2013) · Oncogene · doi:10.1038/onc.2013.518 · Cited by 48
Self-citationCytoplasmic p21 Mediates 5-Fluorouracil Resistance by Inhibiting Pro-Apoptotic Chk2
Maiuthed, A., Ninsontia, C., Erlenbach‐Wuensch, K., Ndreshkjana, B., Muenzner, J. K., Caliskan, A., Husayn, A. P., Chaotham, C., Hartmann, A., Roehe, A. V., et al. (2018) · Cancers · doi:10.3390/cancers10100373 · Cited by 46
Romanov, V. S., & Rudolph, K. L. (2016) · Nature Cell Biology · doi:10.1038/ncb3382 · Cited by 45
Rodríguez-Vilarrupla, A., Jaumot, M., Abella, N., Canela-Canela, N., Brun, S., Díaz, C., Estanyol, J. M., Bachs, O., & Agell, N. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.16.7364-7374.2005 · Cited by 44
Mitotic p21Cip1/CDKN1A is regulated by cyclin-dependent kinase 1 phosphorylation
Kreis, N., Friemel, A., Zimmer, B., Roth, S., Rieger, M. A., Rolle, U., Louwen, F., & Yuan, J. (2016) · Oncotarget · doi:10.18632/oncotarget.10330 · Cited by 43
Self-citationLouwen, F., & Yuan, J. (2013) · Oncotarget · doi:10.18632/oncotarget.1096 · Cited by 42
Self-citationMoussa, R., Park, K. C., Kovačević, Ž., & Richardson, D. R. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2018.03.027 · Cited by 41
Cytoplasmic Localization of p21 Protects Trophoblast Giant Cells from DNA Damage Induced Apoptosis
de Renty, C., Depamphilis, M., & Ullah, Z. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097434 · Cited by 40
Huang, Y., Wang, W., Chen, Y., Huang, Y., Zhang, J., He, S., Tan, Y., Qiang, F., Li, A., Røe, O. D., et al. (2013) · Journal of Gastroenterology · doi:10.1007/s00535-013-0900-4 · Cited by 40
Park, S., Wang, X., Liu, R., Lam, K. S., & Weiss, R. H. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.12.7069 · Cited by 39
Small-Molecule Inhibitors of p21 As Novel Therapeutics For Chemotherapy-Resistant Kidney Cancer
Liu, R., Wettersten, H. I., Park, S., & Weiss, R. H. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.13.56 · Cited by 37
Wang, L., Wang, R., Ye, Z., Wang, Y., Xiao, L., Chen, W., Zhang, M., & Cai, C. (2018) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmy129 · Cited by 37
Wang, Z., Sturgis, E. M., Zhang, F., Lei, D., Liu, Z., Xu, L., Song, X., Wei, Q., & Li, G. (2012) · Molecular Cancer · doi:10.1186/1476-4598-11-17 · Cited by 36
Zhao, H., Faltermeier, C. M., Mendelsohn, L., Porter, P. L., Clurman, B. E., & Roberts, J. M. (2014) · Oncotarget · doi:10.18632/oncotarget.2871 · Cited by 35
Cheng, X., Xia, W., Yang, J.-Y., Hsu, J. L., Chou, C., Sun, H., Wyszomierski, S. L., Mills, G. B., Muller, W. J., Yu, D., et al. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.10.126 · Cited by 35
Manapov, F., Muller, P., & Rychly, J. (2005) · Gut · doi:10.1136/gut.2003.036491 · Cited by 35
Function of p21 (Cip1/Waf1/CDKN1A) in Migration and Invasion of Cancer and Trophoblastic Cells
Kreis, N., Friemel, A., Ritter, A., Roth, S., Rolle, U., Louwen, F., & Yuan, J. (2019) · Cancers · doi:10.3390/cancers11070989 · Cited by 35
Self-citationBenson, V., Stöckbauer, P., Hradcová, M., Souček, J., & Haškovec, C. (2003) · Leukemia Research · doi:10.1016/s0145-2126(03)00103-6 · Cited by 34
Loss of p21Cip1/CDKN1A renders cancer cells susceptible to Polo-like kinase 1 inhibition
Kreis, N., Louwen, F., Zimmer, B., & Yuan, J. (2014) · Oncotarget · doi:10.18632/oncotarget.2844 · Cited by 33
Self-citationFollis, A. V., Galea, C. A., & Kriwacki, R. W. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-0659-4_3 · Cited by 32
Yamamizu, K., Schlessinger, D., & Ko, M. S. H. (2014) · Development · doi:10.1242/dev.115436 · Cited by 32
Restoring p53 Tumor Suppressor Activity As an Anticancer Therapeutic Strategy
Martinez, J. D. (2010) · Future Oncology · doi:10.2217/fon.10.132 · Cited by 31
Masson, A. O., Hess, R., O’Brien, K., Bertram, K. L., Tailor, P., Irvine, E., Ren, G., & Krawetz, R. J. (2015) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2015.05.005 · Cited by 30
Askari, M., Sobti, R. C., Nikbakht, M., & SHARMA, S. C. (2013) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-013-1696-5 · Cited by 30
Zhang, Y., Yan, W., Jung, Y.-S., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066464 · Cited by 28
Ping, B., He, X., Xia, W., Lee, D., Wei, Y., Yu, D., Mills, G. B., Shi, D., & Hung, M. (2006) · PubMed · Cited by 27
Wani, M. A., Wani, G., Yao, J., Zhu, Q., & Wani, A. A. (2002) · Carcinogenesis · doi:10.1093/carcin/23.3.403 · Cited by 27
Cited by
Role of p53 in the Regulation of Cellular Senescence
Mijit, M., Caracciolo, V., Melillo, A., Amicarelli, F., & Giordano, A. (2020) · Biomolecules · doi:10.3390/biom10030420 · Cited by 639
“The p53/p21cip1 axis in the context of cellular senescence has been implicated in several cancer types, including breast cancer, cholangiocarcinoma, head and neck squamous cell cancer, liver cancer, lung cancer, colorectal cancer, as well as ovarian cancer [102].”
BackgroundResearch progress on interferon and cellular senescence
Wang, D., Chen, K., Wang, Z., Wu, H., & Li, Y. (2024) · The FASEB Journal · doi:10.1096/fj.202400808rr · Cited by 23
Metadata
- Authors
- Kreis, N.-N., Louwen, F., & Yuan, J.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2019-08-21
- Volume
- 11
- Issue
- 9
- Pages
- 1220
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W2969845879
- Cited by
- 298
- References
- 213
- FWCI
- 13.24
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.